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4Outcomes reported in randomized controlled trials in peritoneal dialysis (PD) are diverse, are measured
inconsistently, and may not be important to patients, families, and clinicians. The Standardized Out-
comes in Nephrology–Peritoneal Dialysis (SONG-PD) initiative aims to establish a core outcome set
for trials in PD based on the shared priorities of all stakeholders. We convened an international SONG-
PD stakeholder consensus workshop in May 2018 in Vancouver, Canada. Nineteen patients/care-
givers and 51 health professionals attended. Participants discussed core outcome domains and
implementation in trials in PD. Four themes relating to the formation of core outcome domains were
identiﬁed: life participation as a main goal of PD, impact of fatigue, empowerment for preparation and
planning, and separation of contributing factors from core factors. Considerations for implementation
were identiﬁed: standardizing patient-reported outcomes, requiring a validated and feasible measure,
simplicity of binary outcomes, responsiveness to interventions, and using positive terminology. All
stakeholders supported inclusion of PD-related infection, cardiovascular disease, mortality, technique
survival, and life participation as the core outcome domains for PD.Introduction
Peritoneal dialysis (PD) is a cost-effective dialysis modality
that enables patients to have a greater degree of autonomy
and freedom compared with hemodialysis.1 However,
major challenges to the uptake and longevity of PD remain,
including technique failure, infection, catheter problems,
and treatment burden.2,3 Despite the increasing number of
trials aiming to improve outcomes for patients receiving
PD, the evidence for interventions to improve patient-
important outcomes remains limited by the predominant
use of surrogate end points that have not been validated
and highly heterogeneous outcomes, many of which may
not be relevant to patients.4,5
Mortality and technique failure are reported in only
38% and 29% of trials, respectively.6 Outcomes related to
quality of life, including flexibility with time, the ability to
travel or work, and fatigue, are of high priority for patients
receiving PD and their families.7 However, quality of life is
reported in <15% of trials in PD, and fatigue, in <5% of
trials.6 The absence of patient-important outcomes in tri-
als8,9 in nephrology more generally and other medical
specialties is well recognized. Initiatives such as the Core
Outcome Measures in Effectiveness Trials (COMET),
Outcome Measures in Rheumatology (OMERACT), and
Standardized Outcomes in Nephrology (SONG) have been
launched to bring together patients, caregivers, and health
professionals to identify critically important outcomes, to
ensure that trials consistently report relevant and mean-
ingful outcomes to better inform shared decision
making.10-1304The SONG-PD initiative commenced in 2016 and aims
to develop a core outcome set to be reported in all trials in
PD.7,14,15 A core outcome set is defined as an agreed
minimum set of standardized outcomes to be measured
and reported in all trials in a defined clinical population.16
Having identified a consensus-based prioritized list of
outcome domains through an international online Delphi
survey,15 a consensus workshop was convened for pa-
tients, caregivers, and health professionals to review and
discuss the potential core outcome domains. The aim of
this workshop report is to describe stakeholders’ perspec-
tives and considerations on the core outcome set for PD
and to establish the core outcome set to be used in all trials
in PD.
SONG-PD Consensus Workshop
Overview and Context
The SONG-PD consensus workshop was convened at
the 17th Congress of the International Society for
Peritoneal Dialysis (May 7, 2018) in Vancouver, Can-
ada, to elicit stakeholder perspectives on the potential
core outcome set for PD. The potential core outcomes
were based on data from an international 3-round
Delphi survey that was completed online by patients,
caregivers, and health professionals with experience or
expertise in PD. The Delphi survey included outcome
domains reported in trials in PD, as well as from
previous studies with patients receiving PD.7 The
SONG-PD process for establishing core outcome do-
mains is shown in Figure 1.AJKD Vol 75 | Iss 3 | March 2020
Phase 1 | Systemac review
Phase 4 | Delphi Survey
Phase 5 | Consensus workshop
• Three-round survey with outcomes 
idenﬁed from systemac review and 
nominal groups
i. Parcipants rate the importance of each 
outcome on a Likert scale from 1 to 9
ii. Parcipants provide comments (oponal)
iii. Parcipants suggest new outcomes
iv. Best-worst scale
• Top 3-5 outcomes based on means, 
medians, proporons, best-worst scale 
scores
• Idenfy outcomes in RCTs involving adults 
on PD
• Review potenal core outcome set
• Discuss strategies for implementaon
Finalize core outcome domains
• Integrate workshop discussion
• Elicit public/stakeholder comments
• Finalize core outcomes
Phase 2 | Nominal groups
• Paents (aged 18+ years) and caregivers 
idenfy and priorize outcomes, and 
discuss reasons for their choices
Phase 3 | Stakeholder interviews • Interviews with health professionals 
involved in the care of paents on PD
Figure 1. Standardized Outcomes in Nephrology–Peritoneal
Dialysis (SONG-PD) process. Abbreviations: PD, peritoneal dial-
ysis; RCT, randomized controlled trial.
Special ReportParticipants and Contributors
We invited patients and caregivers with current or previ-
ous experience of PD and health professionals (allied
health, industry representatives, physicians, policy makers,
researchers, and surgeons) to attend the workshop. This
was the first Congress of the International Society for
Peritoneal Dialysis to actively invite patients and caregivers
to attend, and those who registered for the conference
were invited to the SONG-PD workshop. Patients/care-
givers who attended the workshop received CaD$30
reimbursement. Health professionals were purposively
identified to include a range of practice locations, clinical
experience, and roles in research, policy, and industry.
In total, 70 participants (19 patients/caregivers and 51
health professionals) attended the workshop. Patients/
caregivers were from Canada (n = 16), the United States (n
= 2), and Hong Kong (n = 1). Health professionals were
from 13 countries, including Canada (n = 12), the United
States (n = 8), Australia (n = 8), United Kingdom (n = 5),
Singapore (n = 4), Hong Kong (n = 3), Brazil (n = 3),
Belgium (n = 2), Japan (n = 2), Bangladesh (n = 1),
Lebanon (n = 1), Poland (n = 1), and South Korea (n = 1).
Workshop contributors (n = 69) were patients/caregivers
and health professionals who provided feedback on the
preworkshop materials and preliminary report but were
unable to attend the workshop in person. Overall, health
professionals had a broad range of experience and exper-
tise in clinical nephrology (including PD) and research
(epidemiology, clinical trials in PD, outcomes, andAJKD Vol 75 | Iss 3 | March 2020outcome measures). Some participants held leadership or
advisory positions in major national and international
professional societies (eg, International Society for Peri-
toneal Dialysis and International Society of Nephrology),
as well as research, policy, regulatory, funding, industry,
and consumer organizations.
Workshop Program and Materials
Participants received the workshop program 1 week in
advance. During the workshop, an overview of the SONG-
PD process, results of the Delphi survey, and a list of po-
tential core outcomes were presented. Participants were
allocated to 7 breakout groups with 8 to 12 members, and
each group included patients/caregivers, physicians, pol-
icymakers, and industry representatives to allow for a
diverse exchange of ideas, knowledge, and experience.
Each facilitator was provided with a question guide (Item
S1) before the workshop.
Facilitators asked participants to reflect and comment on
the potential core outcomes identified in the SONG-PD
Delphi survey. Three to 5 outcome domains are recom-
mended in a core outcome set for feasibility and should
include at least 1 patient-reported outcome (ie, an
outcome that is directly reported by the patient and reflects
how they feel or function).10 Seven outcome domains
were identified as critically important from the Delphi
survey: PD-related infection, membrane function, PD
failure, cardiovascular disease, catheter complications,
death, and life participation.15 Although fatigue did not
meet the threshold ratings for critical importance, it was
the second highest rated patient-reported outcome.
Therefore, we included questions about combining clinical
outcomes (PD infection, membrane function, and catheter
complications) and selection of a patient-reported
outcome (life participation or fatigue). During the final
plenary discussion, the Chair (D.W.J.) asked the nomi-
nated speaker from each breakout group to provide a
summary of their discussion.
All breakout and plenary discussions were audiotaped
and transcribed. Transcripts were entered into Hyper-
Research (ResearchWare Inc, version 3.0) to facilitate
coding and analysis of the data. K.E.M. inductively iden-
tified and coded concepts into themes reflecting the range
of perspectives on the core outcome domains for PD.
Summary of Workshop Discussion
Overview
The discussion was summarized into themes relating to the
identification of the core outcome domains and consid-
erations for implementation, which are described in the
following section. Selected quotations supporting each
theme are provided in Box 1. Box 2 provides a summary of
recommendations based on the workshop discussions.
Figure 2 reveals the SONG-PD core outcome domains.405
Box 1. Selected Quotations From the Workshop Discussions to Illustrate Each Theme
Identiﬁcation of Core Outcomes
Life participation as a main goal of PD
Reﬂecting the need for ﬂexibility and freedom
“People that choose PD want to participate [in life], do all these other things. It’s the reason why they selected PD, that’s what
brings value in their selection of PD, and studying what the intervention does to that may be more meaningful than studying
fatigue.” [G3, health professional]
“…I ﬁnd being able to work and have a life is super important with PD and being on PD, and having the choice doing PD.” [G3,
patient]
“Life participation, being able to work, being able to maintain that schedule and ﬂexibility and travel is super important. To me I’ll
put that higher.” [G3, patient]
An indicator of treatment success
“It always bugs me just a little bit when, with each visit to my PD department, the nurses, the social workers, they come around
and they want to know are you eating? How are you doing with it, are you still comfortable doing your PD? What they don’t ever
ask at all is are you doing anything outside of it? Are you maintaining your activity? Are you putting in your interest time? Have
you still got your hobby you’re doing? Any number of things like that I think would be a more important tell of where the patient
was.” [G7, patient]
“If you told me that someone’s fatigue on PD went up and down depending on the time of the day, the day of the week, the month of
the year, the season. I would be less inclined to say this is a standard outcome where depending on when you catch the patient you’re
going to get a different metric of fatigue, whereas if life participation activities was like the hemoglobin A1c of an overall outcome like I
would think from day to day would ﬂuctuate less, so a more robust measure over time.” [G1, health professional]
“I’d be more interested in the paper that tells me about life participation because I think that more holistically covers what I’m
more interested in about my life.” [G1, patient]
Impact of fatigue
“As a caregiver, I would like to say that fatigue for my client is probably the number one issue. It relates more work for the caregiver
and the lack of exercise, the lack of get-up-and-go, the lack is a constant worry that things are diminishing. As a caregiver I would
think that this is an important thing to be discussing. As a client, he’s probably… this is nice, I’ll just turn on the TV.” [G6, caregiver]
“The more tired, the more discouraged, or the more sick and weak one feels, the less you’re going to do.” [G7, patient]
“I went to school and I still did everything but I was still tired. I participated in what I wanted to do, but I probably picked and
chose what I could do.” [G2, patient]
“I’ll say there’s also the component of emotional fatigue. Sometimes for people who have been doing PD for such a long time,
they’re just exhausted emotionally about the day in, day out of having these tasks that they have to do.” [G6, health professional]
Empowerment for preparation and planning
“I know nowhere near enough detail about the process that you people do, but as far as I’m concerned, that membrane is the
only thing that’s diffusing the stuff out of me. If it isn’t doing it, I’m back in hemo[dialysis] which I don’t want. Literally, that is my
deﬁnition of failure.” [G7, patient]
“I really believe [membrane function] is an important one, because I was not aware of it until it happened to me. When I went on
PD, I thought I’ll be on PD until I get a transplant. Then four years ago, they said no. No more, it’s not working. I was shocked
because I didn’t know that was something that could happen. I think that’s very important. Extremely important.” [G5, patient]
“With the membrane function, I think as patients it’d be nice to know about what it is exactly and the tests, any tests, the results
of the tests and stuff to know so that we have more information. Because I know sometimes as patients we want to know all the
information [about our membrane function], because then later on if something happens then we can understand, okay, when
they’re explaining it to us. Okay, that makes sense and this is why. Getting more information for patients, I think is a huge thing.
Having to know membrane function would be nice.” [G3, patient]
Separation of contributing factors from core
“Membrane failure is a cause of technique failure and that’s the main issue with it. Catheter complications can be far less than
technique failure, it can be pain or the catheter not working very well, which is very common.” [G2, health professional]
“If you report all catheter complications there’s tons of them happening all the time. And it really depends on the severity of them,
and if it’s a core one it would be very difﬁcult to track…If you restrict them to ones that are PD terminating or PD interrupting,
then it’s a much shorter list. It’s kind of similar to membrane function, so I don’t think catheter complications in themselves should
be a core measurement.” [G4, health professional]
“The failure of the technique is more important than the membrane as a core outcome for these trials.” [G5, health professional]
“It’s special because peritonitis in particular is an important thing to capture independent of its cause of failure.” [G5, health
professional]
(Continued)
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Box 1 (Cont'd). Selected Quotations From the Workshop Discussions to Illustrate Each Theme
Considerations for Implementation
Standardizing patient-reported outcomes
“Some people like to do more, some people like to do less, and so again I think the challenge will be to establish boundaries.”
[G1, health professional]
“For each individual person, it will be slightly different. There are some people that just want to be able to go to the shops every
day…Whereas some people want to go back to work.” [G4, health professional]
“On the cultural side it will be very different. I guess socioeconomic status, developed and developing countries to have very
standardized [measures of] life participation would be quite hard.” [G1, health professional]
Requiring a validated and feasible measure
“When we do these trials and measure quality of life, we often have these instruments that are seventy questions, then we have
you do them every three months, and there’s ﬁve different questionnaires. Would you have the appetite to answer those
questions?” [G5, health professional]
“We need to abbreviate the instruments we use to measure your quality of life or your life participation to make them more
manageable.” [G5, health professional]
“At the end of the day that’s the purpose, to try and identify what’s important and then ﬁnd tools to measure how to effectively
measure that outcome.” [G3, health professional]
Simplicity of binary outcomes
“The way I look at it PD failure is like a mortality outcome, you die, PD is not working you have to switch to HD. Membrane
functioning is different.” [G1, health professional]
“Technique failure may be an easier thing to identify in a binary fashion. You are on PD or you’re not on PD, whereas evaluating
membrane function may have different metrics depending on the researcher that’s doing it, and that may make standardizing this
as a reportable outcome difﬁcult.” [G1, health professional]
“Membrane function is sort of an esoteric [outcome]. It’s whether it works or not, that’s tangible.” [G7, health professional]
Responsiveness to interventions
“You could end up with trials that have got nothing to do with the membrane at all having to do membrane function tests simply
to answer this part of the question and that actually adds burden to the trial, it really could be a negative thing.” [G1, health
professional]
“If you’re laying a blueprint that’s going to put this burden on every single study that’s going to be conducted for the rest of time,
you really have to think of the cost implications.” [G4, health professional]
“If we are talking about the outcomes for clinical trials, there may be trials looking at aspects we hardly imagine would affect
membrane function. We would always be interested to know whether there is any effect on PD failure. Say for example, we talk
about treatment of anemia in PD patients—why on earth do we report membrane function?” [G5, health professional]
Using positive terminology
“Failure does sound like something scary.” [G4, patient]
“The worst is when I’ve heard staff say ‘oh the patient failed PD.’ Of course you didn’t fail PD.” [G3, health professional]
“Our table was trying to not use the pejorative in PD failure, but talking about technique survival, modality transitions, and it was
unanimous.” [G3, health professional]
“From a patient point of view it sounds very negative, PD failure, it fails. But actually it may be the right thing, if somebody’s come
off PD.” [G4, health professional]
Abbreviations: G, group; HD, hemodialysis; PD, peritoneal dialysis.
Special ReportIdentiﬁcation of Core Outcome Domains
Life Participation as a Main Goal of PD
Reﬂecting Need for Flexibility and Freedom. The
reasons why patients chose PD as their preferred treatment
modality included the desire to have the flexibility and
autonomy to enable patients “to work and have a life.”
Some patients emphasized the importance of life partici-
pation in PD by comparing it to their experiences on he-
modialysis: “with PD I find I can work and I can do more
things. You have your fatigue days and weeks maybe, but
it’s way better than sitting at home and not working, andAJKD Vol 75 | Iss 3 | March 2020not having to worry about not being able to work.” For
these reasons, many participants prioritized life participa-
tion over fatigue as the core patient-reported outcome.
An Indicator of Treatment Success. Participants
regarded life participation to be as important as key clinical
outcomes, such as cardiovascular disease, infection, or
mortality, explaining that simply by being alive you could be
“a success from the medical point of view,” but this did not
take into account many important aspects of the patient’s
life, including their interests, activities, or hobbies. Some
health professionals thought that life participation “from day407
Box 2. Key Workshop Recommendations for Establishing and
Implementing Core Outcome Domains for PD
Core outcome domains for PD should:
• capture the patient priorities of life participation.
• reﬂect patient goals of maximizing technique survival (ie,
avoiding transfer to hemodialysis).
• be relevant for patients from all backgrounds and cultures.
• be attributed to a single outcome (ie, not combining multiple
related outcome domains). Factors contributing to low
technique survival or life participation may be disaggregated
and addressed separately in trials if researchers wish to do
so.
Implementation of core outcomes requires:
• outcome measures validated in the PD population.
• ease of administration with minimal additional resources.
• positively framed or neutral terms.
Abbreviation: PD, peritoneal dialysis.
Special Reportto day would fluctuate less, so is a more robust measure over
time” and therefore would be a more suitable core outcome
than fatigue. Other health professionals thought that a study
reporting changes in fatigue would be “much more mean-
ingful” than reports of changes in life participation. How-
ever, some patients were more interested to know about
their life participation because it “holistically” encompassed
what was important in their lives.
Impact of Fatigue
Participants recognized that fatigue was a “major factor”
that affected patients and could make a patient feel “totally
wiped out.” While fatigue was recognized by some par-
ticipants as its own distinct issue, many participants were1 CORE OUTCOMES
Critically important 
to all stakeholder groups
Report in all trials
2 MIDDLE TIER
Critically important to 
some stakeholder groups
Report in some trials
3 OUTER TIER
Important to some or 
all stakeholder groups
Consider for trials
1
SONG-PD
1 2 3
PD-INFECTION
CARDIOVASCULAR 
DISEASE
MORTALITY
TECHNIQUE SURVIVAL
LIFE PARTICIPATION
Figure 2. Standardized Outcomes in Nephrology–Peritoneal Dialy
toneal dialysis.
408concerned about the effects of fatigue on a patient’s ability
to participate in life. Caregivers expressed that it “prohibits
[the patient] to do things,” creates “more work for the
caregiver,” and results in diminished quality of life for the
patient because they “couldn’t do the usual small things
that [they] would like.” Patients discussed how they could
“continue to do what they choose to do, but it might not
be to the best of their ability because of their fatigue,”
suggesting that it is important to recognize not just one’s
ability to do something, but “how bad you feel when you
try to do something.” Some participants also considered
fatigue to incorporate a mental component, including
emotional fatigue and depression, which they thought was
a “tremendously important aspect that needs to be dealt
with.”
Empowerment for Preparation and Planning
When considering the proposed core clinical outcomes,
patients thought that it was extremely important to be
mentally and physically equipped to deal with potential PD
failure because there was a “fear and expectation that
things have to go well.” Some patients thought that they
knew “nowhere near enough detail about the process” and
were “shocked” when they experienced unexpected
complications such as membrane failure and had to tran-
sition to hemodialysis. Patients wanted more information
about their membrane function to be best able to keep
themselves “on the healthy side of the line” because it was
generally agreed that “what matters to [patients] is how
long they can stay on PD.”
Separation of Contributing Factors From Core
Participants acknowledged that both membrane function
and catheter complications were contributing factors to PDsis (SONG-PD) core outcome domains. Abbreviation: PD, peri-
AJKD Vol 75 | Iss 3 | March 2020
Special Reportfailure. However, health professionals believed that there
were “so many catheter complications” that did not result
in PD failure and “can often be overcome.” Patients re-
flected similar sentiments regarding the significance of
catheter complications: “[the catheter] is an outside
connection. You mess it up, you got to redo it, but it’s not
[as important as] the kidney, the membrane, the function.
That catheter can’t make me healthy.” As with membrane
function, participants regarded catheter complications to
be important based on the potential to cause PD failure;
“ultimately what we’re talking about is whether it can
support peritoneal dialysis or not.” PD-related infection
was also recognized as a contributing factor to PD failure.
However, some health professionals thought that it was
valid as a “standalone [core] outcome” because it is “an
important thing to capture independent of its cause of
failure."
Considerations for Implementation
Standardizing Patient-Reported Outcomes
Participants discussed the subjectivity of life participa-
tion and agreed that it “depends how much people want
to do” and would be “understood differently for
different people.” This was particularly pertinent when
considering the applicability of this outcome across
countries because it was recognized that the “culture
difference[s]” would result in varying levels and pref-
erences for life participation. Participants also thought
that there may be “many aspects of life participation that
you may want to assess” because some patients may
consider life participation as being able to “go to the
shops,” while for others, it may mean being able to “go
back to work.”
Requiring a Validated and Feasible Measure
Participants agreed that there was “no validated way of
measuring life participation” and so conferred about
existing instruments that measured similar concepts, such
as quality of life. Health professionals commented that
these existing instruments were “really difficult” and ask
“too many questions”; therefore, the measure for life
participation needs to be “more manageable” than existing
related measures. Some participants recognized that fatigue
was a core outcome in hemodialysis (SONG-HD) and
thought that it might be appealing to have the same
outcome for both dialysis modalities to facilitate uptake of
the patient-reported outcome and enable comparison
across modalities. However, participants agreed that it was
necessary to identify what outcomes are most important
for PD.
Simplicity of Binary Outcomes
Health professionals considered the effort required to
measure the clinical core outcomes in all trials and thought
that an outcome measured in a binary way, such as mor-
tality or PD failure, would be “an easier thing to identify”AJKD Vol 75 | Iss 3 | March 2020and standardize as a reportable outcome: “death is very
easy to measure, because it’s just yes or no, did it happen.
That wouldn’t be a big deal to layer death into every single
trial that’s ever done.” Some health professionals also
agreed that it is “much easier to measure PD failure” than
membrane function because it is more “tangible” and “like
a mortality outcome”—“you are on PD or you’re not on
PD.” However, others recognized the nuances and com-
plexities of defining and measuring PD failure because
there are different “levels of interruption or delay” that
should not necessarily be considered PD failure, hence the
need for a standardized definition.
Responsiveness to Interventions
When considering the applicability of the potential core
outcomes to PD trials, health professionals thought that
outcomes, such as membrane function and catheter com-
plications, were “not really relevant” and “just not prac-
ticable” as core outcomes to be reported in all trials. They
believed that the resources required to measure and report
outcomes that are not relevant to all interventions would
place a “burden on every single study.” However, health
professionals believed that some critically important out-
comes, including PD-related infection, cardiovascular dis-
ease, mortality, and PD failure, should always be reported
regardless of the intervention; “we would always be
interested to know whether there is any effect on PD
failure.”
Using Positive Terminology
Participants thought that the inclusion of the word “fail-
ure” in the outcome “PD failure” was considered “pejo-
rative” and a “negative term.” Some patients thought that
failure “sound[s] like something scary” and health pro-
fessionals also noted that there is “a very negative
connotation that shifts everybody’s attitudes a certain way”
when a patient discontinuing PD for any reason is termed a
failure. Positively framed alternatives were suggested,
including “technique survival” and “modality transitions.”
Participants also believed that researchers “need to be
really clear” what they mean by PD failure because there
are many reasons why a patient may discontinue PD and
that “it may be the right thing if somebody’s come off
PD,” therefore it should not be perceived as a failure;
“When I hear PD failure I’m assuming that it is a not
feasible anymore period. It has nothing to do with me
quitting.”Postworkshop Consultation
All participants received a draft workshop report and were
asked to provide feedback within a 2-week time frame.
The SONG-PD core outcome set (Fig 2) was also sent to all
participants for review and comment and was uploaded on
the SONG website for feedback and comment (https://
songinitiative.org/projects/song-pd/). Feedback was in-
tegrated into the final report, and the findings from the409
Special Reportworkshop were used to establish the SONG-PD core
outcome domains.Discussion
Patients who participated in the workshop valued the
flexibility of PD therapy and wanted to preserve and pro-
long technique survival and avoid transfer to hemodialysis,
which were critical for consideration in identifying the
core outcome domains. Fatigue was recognized as a
potentially debilitating symptom that could impair life
participation. Clinical outcomes (ie, membrane function
and catheter complications) that did not necessarily lead to
irreversible PD technique failure were not considered
eligible for use as core outcomes to be reported in all trials.
Key considerations for implementing the core outcome
domains included the need to establish a validated measure
for life participation that is simple to administer and
applicable to all patients, including those in low- and
middle-income countries. Although there was overlap
among life participation and fatigue, as well as membrane
function and PD technique failure, participants believed
that separating these into single-attribute outcomes was
better for clarity. Health professionals acknowledged the
burden of outcome measurement in trials and therefore
agreed that the core outcomes need to reflect what is most
important for all stakeholders to know.
The discussions from this workshop have been used to
establish the core outcome domains to be reported in PD
trials and other forms of research (Fig 2). Participants
agreed that the core outcome domains for PD should
include PD-related infection, cardiovascular disease, mor-
tality, technique survival, and life participation. PD-related
infection, cardiovascular disease, and mortality were
identified in both the Delphi survey and workshop dis-
cussions as core outcomes to be reported in all PD trials
regardless of intervention type. Technique survival, which
was reworded from PD failure to be positively framed, was
regarded by all stakeholders as a highly consequential and
relevant outcome, and as such it was included as a core
outcome domain. Membrane function and catheter com-
plications were not sufficiently relevant for all trials and
were moved to the middle tier. Life participation was
included as the core patient-reported outcome domain,
which reflects the priorities of patients who participated in
the workshop and prior Delphi survey and reinforces the
reason for choosing PD as a dialysis modality. Some health
professionals challenged its inclusion due to measurement
issues of subjectivity and the lack of a standardized vali-
dated measurement tool. However, it was recognized that
the core outcome domains needed to be based on
importance above all other factors.
The importance of autonomy, flexibility, and the ability to
participate in life activities as expressed by patients who
participated in this workshop reinforces findings from prior
studies. A systematic review of qualitative studies on the per-
spectives of patients receiving PD found that patients410appreciated the ability to integrate the treatment into their
daily routines, allowing them to maintain a sense of
normality.17 They also emphasized that PD, as a home-based
therapy, enabled patients to travel. In our workshop, partici-
pants agreed that life participation would be a critically
important and meaningful outcome to be reported in all trials
in PD.
Fatigue has been recognized as a severe symptom in both
PD and hemodialysis, although the type, severity, and fre-
quency of fatigue between modalities may differ.18 Recent
systematic reviews of qualitative studies in patients receiving
hemodialysis emphasized the impact of fatigue in terms of
the restrictions it places on a patient’s ability to participate in
activities.18,19 Similar to what was discussed at this work-
shop, the importance of fatigue to patients was mostly
attributed to the impact it had on their lifestyle. In our
workshop, participants indicated that life participation was a
goal of PD, and other studies have shown that patients
choose PD as their dialysis modality because of the freedom
and independence that it offers.20 Fatigue was recognized as
one aspect that affects the overall life participation for pa-
tients receiving PD, but other factors, including the need to
perform exchanges multiple times a day and having to be
constantly vigilant to avoid infection, have also been re-
ported to impact on life participation.17,21 In comparison,
for patients receiving hemodialysis, fatigue has been re-
ported as a predominant concern and one of the main
symptoms that affects quality of life.22
Although workshop participants remarked that no vali-
dated measures for life participation were available for the
PD population, they may not have considered potentially
suitable existing measures (or subscales for life participa-
tion). We will conduct subsequent studies including a sys-
tematic review of measures for life participation in PD and a
consensus workshop on life participation. We will identify
whether an existingmeasure is sufficient or there is the need
to modify an existing measure or develop a new outcome
measure for life participation. In accordance with the
Consensus-based Standards for the Selection of Health
Measurement Instruments–COMET (COSMIN-COMET)
framework,23 we will conduct further work to validate the
potential measure to ensure that it is appropriate for use in
the PD population.
We acknowledge that the number of participants at this
workshop was relatively small. However, the outcomes
discussed at this workshop were informed by a large in-
ternational Delphi survey completed by more than 800
participants, including patients, caregivers, health pro-
fessionals, regulators, and industry.15 We have also con-
ducted a separate workshop on the implementation of core
outcome sets in nephrology (including SONG-PD), which
involved regulators and industry and will be used to inform
strategies for implementing this core outcome set in trials.24
Subsequent core outcome measures for each of the
outcome domains will need to be developed based on the
workshop recommendations outlined in Box 2. This in-
cludes the need for standardized outcome measures thatAJKD Vol 75 | Iss 3 | March 2020
Special Reportare easily administered and validated in the PD population
and do not impose an excessive burden to trials. This will
facilitate the acceptance and uptake of the core outcomes
so that trials and research in PD report outcomes that are
important to patients, their families, and clinicians.Supplementary Material
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